Original Article
Journal of Human Genetics (2007) 52, 117–122; doi:10.1007/s10038-006-0087-0
Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin
Eriko Shikata1, Rei Yamamoto2, Hiroshi Takane1, Chiaki Shigemasa2, Tadasu Ikeda3, Kenji Otsubo1 and Ichiro Ieiri1,4
- 1Department of Hospital Pharmacy, Faculty of Medicine, Tottori University, Yonago, Japan
- 2Department of Molecular Medicine and Therapeutics, Faculty of Medicine, Tottori University, Yonago, Japan
- 3Department of Adult and Elderly Nursing, Faculty of Medicine, Tottori University, Yonago, Japan
- 4Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
Correspondence: Ichiro Ieiri, Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: ieiri-ttr@umin.ac.jp
Received 25 August 2006; Accepted 27 October 2006; Published online 17 November 2006.
Abstract
Organic cation transporters (OCTs) are responsible for the hepatic and renal transport of metformin. In this study we analyzed variants of OCT1 and OCT2 genes in 33 patients (24 responders and nine non-responders) based on the hypothesis that polymorphisms in both genes contribute to large inter-patient variability in the clinical efficacy of metformin. The sequences of the 5'-flanking and coding regions of the two genes of interest were screened by single-strand conformation polymorphism (SSCP) analysis. To compare the causative factors between responders and non-responders, we performed stepwise discriminant functional analysis. Age, body mass index (BMI) and treatment with lipid-lowering agents were demonstrated as positive predictors, and two mutations in the OCT1 gene, -43T > G in intron 1 and 408Met > Val (1222A > G) in exon 7, were negative and positive predictors, respectively, for the efficacy of metformin; the predictive accuracy was 55.5% (P < 0.05). Subsequent study indicated that OCT1 mRNA levels tended to be lower in human livers with the 408Met (1222A) variant, though the differences did not reach the level of significance. In this study it is suggested that OCT1 and OCT2 gene polymorphisms have little contribution to the clinical efficacy of metformin.
Keywords:
Metformin, OCT1, OCT2, Polymorphisms, Pharmacokinetics, Pharmacodynamics
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Olfactomotor activity during imagery mimics that during perceptionNature Neuroscience Brief Communication (01 Nov 2003)
Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapyJournal of Human Genetics Scientific Correspondence
Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphismJournal of Human Genetics Original Article
Molecular epidemiology of C9 deficiency heterozygotes with an Arg95Stop mutation of the C9 gene in JapanJournal of Human Genetics Scientific Correspondence
See all 76 matches for Research
